



incanthera

***Creating an environment in  
which cancer cannot survive***

**January 2020**

Providing new cancer treatments through the  
acquisition, preparation and early  
commercialisation of targeted medicines

- UK oncology focused, targeted drug development company
- Acquiring, preparing and commercialising new oncology technologies
- Multiple asset portfolio
- First commercial deal for Company's asset (EP0015) signed June 2017
- Near to market asset – possible commercialisation within 18 months
- Lean outsourced business model
- Experienced, multi-skilled team
- Diverse portfolio providing newsflow opportunities

# Origins – Institute of Cancer Therapeutics (ICT) Bradford



- ICT established in 2005 to identify and research unique anticancer technologies
- 4-storey purpose-built facility, over 50 research and oncologist specialists
- Multi-disciplinary approach covering drug design, synthesis, screening, pharmacology and Phase I clinical support
- Incanthera founded in 2010 through spin out from ICT to provide commercial outlet for IP technology and research projects
- 10 year pipeline deal with ICT gives Incanthera first access to targeted prodrug therapeutics for the treatment of cancer

***Progressing anticancer medical research***



# Our Approach

---

- Identify cutting edge technologies in oncology
- Acquire intellectual property rights to product opportunities
- Prepare technologies to valuation realisation
- Commercialise through a partner, securing deal that aims to prioritise further development, marketing and early revenues to Incanthera
- Repeat...

# Our Strengths

---

We have established a broad pipeline portfolio

- Not reliant upon one single technology origin
- A pipeline of product opportunities from various sources
- Future-proofed access to new technologies through deal with the ICT

We develop our products with expertise, in preparation for commercialising

- No requirement for the Company to run late-stage clinical trials itself
- R&D expenditure kept to a minimum

We target early commercial deals

- Minimises our investment
- Maximises the potential for near-term revenues

# How do we achieve this?

---

- Through pro-active identification of novel technology
- Through wide-ranging industry experience and relationships which facilitate strategic preparation of the technology for out-licensing
- Through a proven ability to commercialise novel technology
- Through our experienced team ....

# The Team



**Tim McCarthy**  
**Chairman (Board)**

35 year international career, CEO and CFO of public and private biotech & healthcare companies. Non-Executive Chairman of ImmuPharma plc and Supervisory Board member of Expeleon AG

- Corporate & City



**Pawel Zolniercyk**  
**COO**

IP, Tech Transfer and Project Management specialist, with over 10 years experience in IP commercialisation

- IP & Tech- Transfer



**Simon Ward**  
**CEO (Board)**

Founder of Incanthera, former founder, CEO and CSO of private and public specialist biotech & healthcare companies

- Technology & Development



**Laura Brogden**  
**CFO**

Associate of the Chartered Institute of Management Accounts with 17 years' industry experience. Senior accountant with summ.it assist LLP

- Financial Control & Governance



**Alan Warrander**  
**NED (Board)**

Experienced pharma and biotech executive with extensive background in global pharma drug discovery development including AstraZeneca and Wood Mackenzie

- Industry & Licensing



**Suzanne Brocks**  
**Head of Communications**

Accomplished financial communications specialist with over 30 years' City and PR experience, through Hill Samuel and Buchanan Communications

- Shareholders, City & Company




# Growth through Commercial Deals

Year	Deal
2010	Company Founded
2011	Pipeline deal - Institute of Cancer Therapeutics (ICT)
2011	Acquisition of EP0015 (VDA - ICT pipeline)
2014	Acquisition of Onco-NX Ltd (Equin programme)
2014	Acquisition of Duo-C technology (ICT pipeline)
2014	Acquisition of Spear Therapeutics Ltd (Duo-C programme)
2015	Acquisition of EP0015 (theranostic - ICT pipeline)
2016	Acquisition of EP0015 (taxane - ICT pipeline)
2017	Out-licensing of EP0015 to Ellipses Pharma Ltd
2018	Pipeline Extension, ICT
2018	Acquisition of Sol


# Product Pipeline

Acquisition			Preparation for Licensing	Licensing
Platform	Product	Indication		
Sol	Topical Cream	Skin cancers: solar keratosis, melanoma (AK - \$3.4bn)*	Bioequivalence →	Market Launch
EP0015	VDA & Theranostic	Lung, breast, ovarian cancers (\$5.9bn, \$15.3bn, \$1.6bn)*	Pre-clinical →	Licensed to Ellipses Pharma Ltd (2017)
	Taxane	Ovarian, prostate cancers (\$1.6bn, \$8.6bn)*	Lead →	
Equin	DT Diaphorase activation	Liver, brain, pancreatic cancers (\$0.5bn, \$0.35bn, \$2bn)*	Pre-clinical →	
Duo-C	CYP activation	Bladder, colorectal cancers (\$0.36bn, \$8bn)*	Lead →	


\*Market size estimates sourced from external commercial sector reports



- Unique MOA - pro-drug targeting tumour vasculature
- Strong pre-clinical efficacy and safety data
- Delivery platform for highly efficacious 'warheads'



- Bio-reductive Prodrug activated by DT-Diaphorase
- Target cancers include liver and breast with a potential for paediatric indications
- Substantial data available from RH1 trials




- Novel targeted, cyp-activated chemotoxin
- Converted to ultrapotent cytotoxin - no known resistance mechanism
- Development of CYP2W1 biomarker

# Sol and The Skin Cancer Challenge

Skin cancer (including solar keratosis) is the most common form of cancer in white populations, and deaths arising from invasive melanoma are on the increase.

- Melanoma has increased by 45% in ten years
- Melanoma is the fifth most common cancer in young adults
- Rates in the UK increasing by 70% in 25 to 49-year-olds since 1990's




The global market for skin 'sun care' products is projected to reach US\$13.7 billion by 2024 (excluding pharmaceutical products, currently \$3.4bn)\*

\*Market size estimates sourced from external commercial sector reports

# Our Natural Defence

Cells have natural defence and DNA repair capabilities, but this is compromised in skin cells by UV light

A natural agent believed to enhance the skin's defences and DNA repair capabilities, to counter UV effects, has been identified



Studies including a Phase 3 clinical trial have demonstrated that Oral Dosing of this agent:

- Significantly reduces progression of actinic (solar) keratoses and other pre-cancerous lesions to the more deadly melanoma forms
- Reduces recurrence of skin cancer in previously treated subjects prone to skin cancer development

*Dermatological experts in skin cancer believe that Sol's active ingredient could reduce the incidence of actinic keratosis*

# The Opportunity and the Advantages

## Opportunity – Sol

A dermatological preparation of the natural agent to offer significant advantages over oral dosing

### Advantages of Sol over oral dosing

- Avoidance of known possible side effects of ingestion
- Circumvention of first-pass metabolism
- Ease of application
- Direct targeting of sun exposed tissues and lesions
- Opportunity to introduce additional UV protection
- Addition of “do-good” cosmetic skin care ingredient (e.g. anti-ageing)




VS




Independent Proof of Principle Studies conducted at the UCL London School of Pharmacy using human skin penetration models demonstrate that our advanced formulation technology (Summer 2019):

- Exceeds the bioequivalence test
- Delivers a topical product for the prevention of actinic keratosis and skin cancer



# Next Steps

Numerous milestones over next 18 months





Recognition of importance of regular, positive newsflow to support increase in valuation:

- Product Manufacture – Sol
- Storage Stability Data – Sol
- Submission of CTA to MHRA for EP0015
- Safety Data –Sol
- Commencement of First Time in Man trial with EP0015
- Commercial deal - Sol
- Data on EP0015

- Valuation at last fund raise: £13.5m
- Fund Raise: £1.8m
- EIS and VCT qualifying
- Shareholders:

NWF	33.3%
UoB	15.4%
IMM	14.9%
Directors & Mgmt.	7.9%
NPIF (Maven)	1.9%
University of Salford	1.5%
HNWI & Others	25.1%

- Fund Raise: £1.8m
- R & D: £850k
- Board Costs: £160k
- Other Salaries: £130k
- Overheads: £300k
- Costs of Listing: £360k

- Differential business model
    - Acquire, prepare, commercialise
  - Near to market asset
    - Sol potential to launch (with commercial partner) within 18 months with numerous milestone opportunities in the interim
  - Revenue generative through strategic partners (first commercial deal signed)
    - Proves business model to commercialise products at earliest stage
  - Multi-product portfolio
    - Minimises risk of single product development
  - Newsflow
    - Driving shareholder value
-

The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the "Presentation") have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate Incanthera plc (the "Company"). This Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of definitive documentation in final form (which may contain different information from the information contained in this Presentation), and you own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.

By accepting this Presentation you confirm, represent and warrant that you have consented to receive inside information (as defined in the Criminal Justice Act 1993 and the Financial Services and Markets Act 2000 (as amended)), and you agree not to deal in any securities of the Company until such time as such inside information has been made public and until such time that the Placing has been publicly announced by the Company.

This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are confidential and are subject to updating, completion, revision, further verification and amendment without notice.

The Presentation is being distributed on request only to, and is directed at, authorised persons or exempt persons within the meaning of FSMA or any order made thereunder or to those persons falling within the following articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Financial Promotion Order"); Investment Professionals (as defined in Article 19(5)) or are eligible counterparties within the meaning given in COBS 3.6.1 of the FSA Handbook as at 1 November 2007; High Net Worth Companies (as defined in Article 49(2)) and Members or Creditors of the Company (as defined in Article 43(2)) as well as persons to whom distribution may otherwise lawfully be made (all such persons being "Relevant Persons"). Any person who is not a Relevant Person should not rely on this Presentation nor take any action upon it but should return it immediately to the Company.

This Presentation is exempt from the general restriction in section 21 of FSMA relating to the communication of invitations or inducements to engage in investment activity on the grounds that it is made only to certain categories of persons.

Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the "US"), Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship. The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (iii) you have read and agree to comply with the contents of this disclaimer.